Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-01-24
1996-10-01
Ramsuer, Robert W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514252, 514326, 514327, 544130, 544365, 546194, 546214, 546221, A61K 31445, A61K 31535, C07D21142, C07D41306
Patent
active
055611303
DESCRIPTION:
BRIEF SUMMARY
This application is a 371 of PCT/GB 93/01525 filed Jul. 20, 1993.
This invention relates to a class of azacyclic compounds, which are useful as tachykinin antagonists. More particularly, the compounds of the invention comprise an azacyclic ring system substituted by an arylmethyloxy or arylmethylthio moiety.
The tachykinins are a group of naturally-occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in the peripheral nervous and circulatory systems. The structures of three known mammalian tachykinins are as follows:
Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardivascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitus, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C. A. Maggi, R. Patacchini, P. Rovero and A. Giachetti, J. Auton. Pharmacol. (1993) 13, 23-93. Tachykinin antagonists are also believed to be useful in allergic conditions [Hamelet et al Can. J. Pharmacol. Physiol. (1988) 66 1361-7], immunoregulation [Lotz et al Science (1988) 241 1218-21 and Kimball et al, J. Immunol. (1988) 141 (10) 3564-9], and as anticonvulsants [Garant et al., Brain Research (1986) 382 372-8]. Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon et al., Cancer Research (1992) 52, 4554-7].
It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophillic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosis (European patent application no. 0 436 334), conjuctivitis, vernal conjunctivitis, contact dermatitis, atropic dermatitis, urticaria, and other eczematoid dermatitis (European patent application no. 0 394 989) and emesis (European patent application no. 0 533 280).
European patent application no. 0 436 334 discloses 4- to 7-membered azacyclic compounds substituted at the 3-position by a substituted amino moiety. The compounds are said to be tachykinin antagonists.
The present invention provides a compound of formula (I), or a salt or prodrug thereof: ##STR2## wherein n is 1, 2 or 3; selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl --OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 .sup.R.sup.b, --CO.sub.2 R.sup.a and --CONR.sup.a R.sup.b ; selected from indazolyl, thienyl, furyl, pyridyl, thiazolyl, tetrazolyl and quinolyl; benzhydryl; or benzyl; wherein each aryl or heteroaryl moiety may be substituted by C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halo or trifluoromethyl; azacyclic ring and each independently represent H, halo, C.sub.1-6 alkyl, oxo, CH.sub.2 OR.sup.a, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b ; C.sub.1-6 alkyl substituted by C(.dbd.NR.sup.a)NR.sup.b NR.sup.c CO.sub.2 R.sup.d, CONHNR.sup.a R.sup.b, C(S)NR.sup.a R.sup.b, CONR.sup.a C.sub.1-6 alkylR.sup.12, CONR.sup.13 C.sub.2-6 alkynyl, CONR.sup.13 C.sub.2-6 alkenyl, COCONR.sup.a R.sup.b, CONR.sup.a C(NR.sup.b)NR.sup.c R.
REFERENCES:
patent: 4996327 (1991-02-01), Merkle et al.
patent: 5128480 (1992-07-01), Merkle et al.
patent: 5459270 (1995-10-01), Williams et al.
Advances in Heterocyclic Chemistry, Katritzky, vol. 6, 1966.
Pyrazoles, Pyrazolines, Pyrazolidines, Idazoles and Condensed Rings, Behr et al., The Chemistry of Heterocyuclic Compounds, 1967.
Desai, et al., J. Med. Chem. 35(26) pp. 4911-4913 (1992) "Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant".
Chem. Abstracts, 100, Abstract No. 192245m (1984) Columbus, Ohio, US.
J. Chem. Soc., Perkin Trans 1, 1, pp. 29-39 (1984).
Seward Eileen M.
Swain Christopher J.
Merck Sharp & Dohme Limited
Ramsuer Robert W.
Rose David L.
Thies J. Eric
LandOfFree
Azacyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azacyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azacyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1502117